Alto Neuroscience, Inc. (ANRO)

NYQ – Real Time Price. Currency in USD

20.50

-0.32 (-1.54%)

At close: Mar 27, 2026, 4:00 PM EDT

20.93

+0.43 (2.10%)

After-hours: Mar 27, 2026, 6:16 PM EDT

16.03.2026

Alto Neuroscience Announces $120 Million Private Placement Financing

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, announced today that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing (the “PIPE”) for gross proceeds of approximately $120 million, before deducting offering expenses. The financing.

16.03.2026

Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the full year ended December 31, 2025, and highlighted recent progress across its pipeline of clinical-stage product candidates. “Alto enters 2026 with a very strong clinical and financial foundation,” said Amit Etkin, M.D., Ph.D., founder and.

13.03.2026

Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company's management team will participate in a virtual fireside chat at the Stifel 2026 Virtual CNS Forum on March 17, 2026 at 12:00pm ET. The presentation will be accessible via a live webcast on the Events and Presentations page in the Investo.

23.02.2026

Alto Neuroscience Announces Participation in Upcoming Investor Conferences

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company's management team will participate in the following upcoming investor conferences: TD Cowen 46th Annual Healthcare Conference, March 2-5, 2026 Format: Fireside chat and one-on-one meetings Presentation Date & Time: March 3, 2026, 1:50.

13.02.2026

Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the completion of patient enrollment in its Phase 2 proof-of-concept clinical trial evaluating ALTO-101, a novel, transdermal phosphodiesterase-4 (PDE4) inhibitor, for the treatment of cognitive impairment associated with schizophrenia (CIAS). Topline data from the.

03.02.2026

Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #Neuroplasticity--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the publication of a review, "Brain Neuroplasticity Mechanisms in Psychiatric Illnesses and in the Development of Novel Treatments," in the American Journal of Psychiatry. The review was co-authored by members of Alto Neuroscience's leadership team, Patricio O'Donn.

14.01.2026

Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the issuance of U.S. Patent Number 12,521,374 covering methods of treating depression with ALTO-207, a novel combination of pramipexole and ondansetron. The patent protects a key aspect of ALTO-207 – the use of ondansetron to mitigate pramipexole-related side effec.

Alto Neuroscience, Inc. (ANRO)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Alto Neuroscience, Inc. (ANRO)

Alto Neuroscience Announces $120 Million Private Placement Financing

Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights

Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum

Alto Neuroscience Announces Participation in Upcoming Investor Conferences

Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia

Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment

Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression

Alto Neuroscience Announces $120 Million Private Placement Financing

Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights

Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum

Alto Neuroscience Announces Participation in Upcoming Investor Conferences

Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia

Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment

Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression

Videos

No Data

Press releases

Alto Neuroscience Announces $120 Million Private Placement Financing

Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights

Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum

Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia